Oculis (NASDAQ:OCS) Price Target Lowered to $45.00 at Guggenheim

Oculis (NASDAQ:OCS) had its price target lowered by stock analysts at Guggenheim from $75.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 98.23% from the company’s previous close.

Other research analysts have also recently issued reports about the stock. JPMorgan Chase & Co. lifted their price objective on shares of Oculis from $38.00 to $42.00 and gave the company an “overweight” rating in a research note on Monday, May 18th. Needham & Company LLC decreased their price objective on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday. HC Wainwright decreased their price objective on shares of Oculis from $47.00 to $26.00 and set a “buy” rating on the stock in a research note on Monday. Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research note on Saturday, March 7th. Finally, Stifel Nicolaus lifted their price objective on shares of Oculis from $40.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, March 4th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $42.00.

Oculis Stock Performance

Shares of NASDAQ:OCS opened at $22.70 on Monday. The company’s 50 day simple moving average is $27.68 and its 200 day simple moving average is $25.21. The stock has a market capitalization of $1.32 billion, a price-to-earnings ratio of -10.66 and a beta of 0.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.18 and a quick ratio of 5.18. Oculis has a 1 year low of $16.00 and a 1 year high of $34.47.

Oculis (NASDAQ:OCS) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). The firm had revenue of $0.26 million during the quarter, compared to the consensus estimate of $0.25 million. Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. As a group, research analysts predict that Oculis will post -2.21 EPS for the current fiscal year.

Institutional Trading of Oculis

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE lifted its holdings in shares of Oculis by 2.2% during the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after purchasing an additional 878 shares during the period. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Oculis by 100.0% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock worth $40,000 after purchasing an additional 1,000 shares during the period. Aventura Private Wealth LLC acquired a new position in shares of Oculis during the fourth quarter worth $80,000. Geode Capital Management LLC lifted its holdings in shares of Oculis by 27.7% during the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the period. Finally, Koshinski Asset Management Inc. acquired a new position in shares of Oculis during the first quarter worth $238,000. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.